Apolipoprotein E phenotype and blood pressure. 1994

P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E

Related Publications

P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes
January 1994, Lancet (London, England),
P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes
February 1997, The American journal of clinical nutrition,
P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes
December 2004, Nihon rinsho. Japanese journal of clinical medicine,
P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes
November 1998, American journal of hypertension,
P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes
January 1997, Contributions to nephrology,
P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes
April 1999, Clinical chemistry,
P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes
February 1988, L'union medicale du Canada,
P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes
September 1999, American journal of hypertension,
P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes
September 1999, American journal of hypertension,
P de Knijff, and D I Boomsma, and E J Feskens, and J Jespersen, and L G Johansen, and C Kluft, and D Kromhout, and L M Havekes
May 1994, Clinical chemistry,
Copied contents to your clipboard!